Group 1 - The core viewpoint of the news is that Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has shown fluctuations in its stock performance and financing activities, indicating potential investor interest and market dynamics [1][2]. Group 2 - On December 18, Boyuan shares fell by 2.24%, with a trading volume of 66.31 million yuan. The financing buy-in amount was 5.13 million yuan, while the financing repayment was 3.34 million yuan, resulting in a net financing buy-in of 1.79 million yuan. The total financing and securities balance reached 142 million yuan [1]. - As of December 18, the financing balance of Boyuan shares was 142 million yuan, accounting for 3.69% of the circulating market value [1]. - In terms of securities lending, there were no shares repaid or sold on December 18, with a remaining balance of 0 shares and 0 yuan [1]. Group 3 - Boyuan, established on August 6, 2008, is located in Shouguang City, Shandong Province, and specializes in the research, production, and sales of fine chemicals, including organic and inorganic iodides, precious metal catalysts, and luminescent materials. The main business revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. - For the period from January to September 2025, Boyuan achieved an operating income of 1.073 billion yuan, representing a year-on-year growth of 6.60%. However, the net profit attributable to the parent company was 132 million yuan, a decrease of 22.53% year-on-year [2]. Group 4 - Since its A-share listing, Boyuan has distributed a total of 88.41 million yuan in dividends [3]. - As of September 30, 2025, the top ten circulating shareholders of Boyuan include several new institutional investors, with notable holdings from Zhonghang New Start Flexible Allocation Mixed A (holding 1.3456 million shares) and Hong Kong Central Clearing Limited (holding 964,400 shares) [3].